Cerebellar rhythm loss due to climbing fiber regression is a shared pathophysiology of motor deficits across cerebellar ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

Careful monitoring of neurologic function, cardiac function, presence of diabetes, monitoring for scoliosis and visual loss ...

Ataxia is caused by damage in cerebellum, leading to poor muscle control. Know the causes and types of ataxia that can lead to other health complications. Ataxia is a condition caused by damage in ...

Considering taking supplements to treat cerebellar ataxia? Below is a list of common natural remedies used to treat or reduce the symptoms of cerebellar ataxia. Follow the links to read common ...

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

Solid Biosciences' SGT-212, dual-route gene therapy for Friedreich’s ataxia, receives FDA Fast Track designation for expedited development. Solid Biosciences Inc. has announced that its gene ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich ataxia (FA).

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...